Key statistics
As of last trade, Vaxcyte Inc (5VA:FRA) traded at 43.40, 76.42% above the 52 week low of 24.60 set on Apr 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 43.40 |
|---|---|
| High | 43.40 |
| Low | 43.40 |
| Bid | 43.60 |
| Offer | 48.20 |
| Previous close | 43.80 |
| Average volume | 159.71 |
|---|---|
| Shares outstanding | 141.03m |
| Free float | 140.35m |
| P/E (TTM) | -- |
| Market cap | 7.63bn USD |
| EPS (TTM) | -4.84 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 08:11 GMT.
More ▼
Announcements
- Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $550 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
- Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
- Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
- Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
More ▼
